Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2025-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
1Federal University of Sergipe, Aracaju, Brazil
2Aracaju City Hall, Municipal Health Department, Aracaju, Brazil
3Government of Sergipe State, Health Foundation Parreiras Horta, Central Laboratory of Public Health (LACEN/SE), Aracaju, Brazil
© 2023, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variables | RT-qPCR positive/total, n (%) | Prevalence ratio (95% CI) | p-value | |
---|---|---|---|---|
Sex | ||||
Male | 82/399 (20.6) | 1.00 (reference) | ||
Female | 29/95 (30.5) | 1.50 (0.94, 2.30) | 0.075 | |
Age (yr) | ||||
≤39 | 68/251 (27.1) | 1.53 (1.03, 2.30) | 0.028 | |
≥40 | 43/243 (17.7) | 1.00 (reference) | ||
Use of public transport | ||||
No | 16/78 (20.5) | 1.00 (reference) | ||
Yes | 95/416 (22.8) | 1.11 (0.65, 2.03) | 0.712 | |
Frequency of use of public transport (times/wk) |
||||
1-2 | 15/58 (25.9) | 1.00 (reference) | ||
3-4 | 8/35 (22.9) | 0.88 (0.33, 2.22) | 0.795 | |
≥5 | 71/310 (22.9) | 0.89 (0.50, 1.67) | 0.653 | |
COVID-19 vaccine - first dose |
||||
Oxford-AstraZeneca | 10/56 (17.9) | 1.00 (reference) | ||
Pfizer-BioNTech | 77/344 (22.4) | 1.25 (0.65, 2.72) | 0.519 | |
CoronaVac | 12/45 (26.7) | 1.49 (0.59, 3.86) | 0.356 | |
COVID-19 vaccine - second dose |
||||
Oxford-AstraZeneca | 2/13 (15.4) | 1.00 (reference) | ||
Pfizer-BioNTech | 25/115 (21.7) | 1.41 (0.35, 12.31) | 0.699 | |
CoronaVac | 3/12 (25.0) | 1.63 (0.19, 19.46) | 0.626 | |
Vaccination schedule | ||||
Fully vaccinated | 31/145 (21.4) | 1.00 (reference) | ||
Not vaccinated |
80/349 (22.9) | 1.07 (0.70, 1.68) | 0.753 | |
Confidence in the protective effect of vaccines | ||||
Yes | 85/403 (21.2) | 1.00 (reference) | ||
Preferred not to answer | 5/35 (14.3) | 0.68 (0.21, 1.64) | 0.411 | |
No | 21/56 (37.5) | 1.78 (1.05, 2.89) | 0.025 |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-qPCR, quantitative reverse-transcriptase polymerase chain reaction; COVID-19, coronavirus disease 2019; CI, confidence interval. Thirteen individuals did not report the frequency of using public transport. Two subjects received the Janssen vaccine, and 42 subjects had no information about the vaccine received as a first dose. Three individuals had no information about the vaccine received. Only 5 individuals were not vaccinated, of whom 1 tested positive for COVID-19.